A study testing whether an investigational medicine from Novo Nordisk, NNC0721-8060, can help people lose weight.
- Who can join
- Adults 18 to 55, are overweight, BMI 27+.
- What you take
- NNC0721-8060, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
- How long it lasts
- The study runs about 13 months.
- What you get
- Many clinical trials pay for the study medication and the study visits. Some also pay for travel. Ask the study team what this one covers before you sign the consent form.
What this study is for
Primary condition: Overweight. Also studied in: Obesity.
Full scientific study title: A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity.
Who can join
Adults 18 to 55, are overweight, BMI 27+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.
Full medical eligibility (for you and your doctor)verbatim from the registry
This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.
Key inclusion criteria
- Male or female (sex at birth).
- Age 18-55 years (both inclusive) at the time of signing informed consent.
- Body Mass Index (BMI) 27.0-34.9 kilograms per square metre (kg/m\^2) (both inclusive) at screening, with overweight due to excess adipose tissue as judged by the investigator.
- Considered eligible based on medical history, physical examination, vital signs, electrocardiogram and clinical laboratory tests at screening, as judged by the investigator.
Key exclusion criteria
- Known or suspected hypersensitivity to study intervention(s) or related products.
- Previous randomisation in this study.
- History of allergies (with the exception of seasonal allergies) or history of anaphylactic reactions.
- Female who is pregnant, breastfeeding, intends to become pregnant, or is of childbearing potential and not using adequate contraception.
- Current participation (signed informed consent) in any other interventional clinical study.
Where this trial runs
This trial has 2 sites across 2 states. Site contacts are listed for reference. They are not screening through this trial right now.
Kansas1 site
- ICON Early Phase Services, LLCLenexa, Kansas
Texas1 site
- ICONSan Antonio, Texas
Timeline
Scheduled start: August 12, 2026. Expected completion: September 23, 2027. Last updated on ClinicalTrials.gov: August 17, 2026.
Official source
Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked August 19, 2026. Confirm the current status there before you contact a site:
Other GLP-1 clinical trials
Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.
